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Species Specificity of Type III Interferon Activity
and Development of a Sensitive Luciferase-Based
Bioassay for Quantitation of Mouse Interferon-l
Sophie Jacobs,1 Fanny Wavreil,1 Bert Schepens,2,3 Hans Henrik Gad,4 Rune Hartmann,4
Joana Rocha-Pereira,5 Johan Neyts,5 Xavier Saelens,2,3 and Thomas Michiels1
The type III interferon (IFN-l) family includes 4 IFN-l subtypes in man. In the mouse, only the genes coding
for IFN-l2 and -l3 are present. Unlike mouse and human type I IFNs (IFN-a/b), which exhibit strong species
specificity, type III IFNs were reported to act in a cross-specific manner. We reexamined the cross-specificity
and observed that mouse and human IFN-l exhibit some species specificity, although much less than type I
IFNs. Mouse IFN-l3 displayed clear species specificity, being 25-fold less active in human cells than the
closely related mouse IFN-l2. This specificity likely depends on amino acids in a helices A and F that diverged
from other IFN-l sequences. Human IFN-l4, in contrast, retained high activity in mouse cells. We next
developed a firefly luciferase-based reporter cell line, named Fawa-l-luc, to detect IFN-l in biological fluids
with high specificity and sensitivity. Fawa-l-luc cells, derived from mouse epithelial cells that are responsive to
IFN-l, were made nonresponsive to type I IFNs by inactivation of the Ifnar2 gene and strongly responsive to
IFN-l by overexpression of the mouse IFNLR1. This bioassay was as sensitive as a commercially available
enzyme-linked immunosorbent assay in detecting mouse IFN-l in cell culture supernatant, as well as in serum
and bronchoalveolar lavage samples of virus-infected mice. The assay also enabled the sensitive detection of
human IFN-l activity, including that of the divergent IFN-l4 with a bias, however, due to variable activity of
IFN-l subtypes.
Keywords: species-specific activity, cross-species activity, IFN-l receptor, IFN-l, type I IFN, antiviral,
cytokine, respiratory syncytial virus
Introduction
Type I and III interferons (IFNs) are typically pro-duced in response to viral infection, and these cytokines
induce an antiviral state in target cells (Isaacs and Linden-
mann 1957; Kotenko and others 2003; Sheppard and others
2003). Type I IFNs consist of 13 IFN-a subtypes and IFN-b,
-o (human), and -z (mouse) -e and -k. The type III family of
IFNs in humans comprises 3 functional genes that express
IFN-l1 (IL-29), IFN-l2 (IL-28A), and IFN-l3 (IL-28B)
(Kotenko and others 2003; Sheppard and others 2003).
A fourth IFN-l subtype (IFN-l4) is present in a part of the
human population, depending on a dinucleotide frameshift
polymorphism upstream of the IFNL3 gene, which creates
or disrupts the open reading frame (ORF) encoding IFN-l4
(Prokunina-Olsson and others 2013). In the mouse, Ifnl1 is a
pseudogene, and only IFN-l2 and IFN-l3 are expressed.
Unlike mouse and human type I IFNs that exhibit strongly
species-specific activity (Veomett and Veomett 1979), type
III IFNs were reported to act on cell types from both origins
(Lasfar and others 2006; Hermant and others 2014).
The type I IFN family members signal through a unique
heterodimeric receptor (IFNAR), composed of the IFNAR1
and IFNAR2 subunits. Type III IFNs engage a distinct
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receptor (IFNLR), composed of 2 chains: the IFN-l-specific
IFNLR1, and IL10Rb which is shared by other IL10-related
cytokines (Kotenko and others 2003; Sheppard and others
2003). While IFNAR is ubiquitously expressed, IFNLR is
expressed by a restricted range of cell types and mostly acts
at mucosal surfaces. Epithelial cells are well-established
targets of IFN-l in vivo (Sommereyns and others 2008),
although some immune cells such as neutrophils and den-
dritic cells have been characterized as IFN-l responders
(Koltsida and others 2011; Blazek and others 2015; Broggi
and others 2017; Espinosa and others 2017).
Although type I and type III IFNs act on distinct recep-
tors, they activate a similar JAK-STAT transduction path-
way, leading to the phosphorylation of STAT1 and STAT2
that associate with IRF9 to form the ISGF3 complex. Type I
and type III IFN signaling leads to the transcription of an
overlapping set of IFN-stimulated genes (ISGs) (Dumoutier
and others 2004; Ank and others 2006).
Type I IFN in biological samples can be measured by a
variety of bioassays, but efficient techniques for type III IFN
quantification are largely lacking. Enzyme-linked immu-
nosorbent assay (ELISA) for IFN-l detection is time and
cost intensive and fails to detect IFN-l4. Conventional cy-
topathic effect reduction bioassays to quantify antiviral
activity as a proxy for the presence of IFN require the ma-
nipulation of infectious virus. Luciferase reporter cells that
have previously been used for recombinant human IFN-l
detection were still responsive to type I IFN and would not
allow specific IFN-l detection from biological samples (Uze
and Monneron 2007). In this work, we reexamined the
species specificity of IFN-l activity, and we developed a
very sensitive luciferase-based bioassay specific for type III
IFN detection.
Materials and Methods
Cell culture
The LKR10 cell line (kind gift from Guido Bommer, de Duve
Institute, Brussels, Belgium) is derived from lung adenocarci-
noma tissues from a K-rasLA1 mouse (Johnson and others
2001). A549 cells (ATCC) were kindly provided by Pierre
Coulie, BALB/3T3 fibroblasts (Aaronson and Todaro 1968) by
Francis Brasseur (Ludwig Institute for Cancer Research, Brus-
sels, Belgium), and Hela-M (Dong and others 2001) by Robert
H. Silverman (Lerner Research Institute, Cleveland).
Those cells, and derivatives, were maintained in Dul-
becco’s modified Eagle’s medium (DMEM) (Lonza, Ver-
vier, Belgium) containing 4.5 g/L glucose, supplemented
with 10% fetal calf serum (FCS) (Sigma-Aldrich, Overijse,
Belgium). African green monkey kidney (Vero) cells
(ATCC) were cultured in DMEM supplemented with 10%
FCS, nonessential amino-acid, l-Glutamine, and sodium
pyruvate. BHK-21 cells (ATCC) were cultured in Glas-
gow’s minimum essential medium (Gibco; Thermo Fisher
Scientific, Asse, Belgium) supplemented with 10% newborn
calf serum and 2.95 g/L tryptose phosphate broth. All media
were supplemented with 50 U/mL penicillin and 50 mg/mL
streptomycin (Lonza).
Vectors
Expression vectors used in this study are listed in Table 1.
Plasmids pSJ1 and pSJ7 are pcDNA3 derivatives (Invitrogen;
Thermo Fisher Scientific) used for mouse IFN-l2 and IFN-l3
expression in 293T cells. These plasmids were constructed by
cloning the ORF encoding IFN-l2 (pSJ1) and IFN-l3 (pSJ7)
between the BamHI and XbaI sites of the vector. Coding
sequences were polymerase chain reaction (PCR)-amplified
from liver cDNA samples of a C57BL/6 mouse infected with
influenza TURH (H7/N1) strain (Hermant and others 2014),
using the following primers: Forward (Fw): BamHI-AgeI-
Kozak-mIFN-l2/3, 5¢-AAA AGG ATC CAC CGG TGC
CAC CAT GCT CCT CCT GCT GTT GCC TCT G-3¢;
Reverse (Rev): mIFN-l2/3-stop-XbaI, 5¢-AAA ATC TAG
ATT ATC AGA CAC ACT GGT CTC CAy TGG C-3¢.
The sequence of pSJ7 matches the genomic Ifnl3 se-
quence but diverges from a few nucleotides from that of the
previously constructed pCS59 plasmid (Sommereyns and
others 2008). Both plasmids encode functional IFN-l3.
pPH23 was obtained by PCR-cloning the IFNA2 ORF from
Hela-M cell cDNA, between the EcoRI and NotI sites of
pcDNA3 (Fw: EcoRI-Kozak-IFNa2, 5¢-AAA AGA ATT
CAC CAT GGC CTT GAC CTT TGC TTT-3¢; Rev: IFNa2-
Table 1. Expression Plasmids Used in This Study
Vectors Protein expressed, particularity Type (parental vector)
CRISPR-Cas9 nickase expressing vectors
pSJ37 sgRNA 1-exon 6 mouse IFNAR2c Plasmid (px461)
pSJ38 sgRNA 2-exon 6 mouse IFNAR2c Plasmid (px461)
IFN-a expression plasmids
pcDNA3-IFNaA IFNaA-mouse Plasmid (pcDNA3)
pPH23 IFNa2-human Plasmid (pcDNA3)
IFN-l expression plasmids
pSJ1 IFN-l2-mouse (C57bl/6 genomic sequence) Plasmid (pcDNA3)
pSJ7 IFN-l3-mouse (C57bl/6 genomic sequence) Plasmid (pcDNA3)
pCS59 IFN-l3-mouse (pEF-2-mIFN-l3 derivative) Plasmid (pcDNA3)
Lentiviral constructs
pMK03 Mx1-promoter-Firefly luciferase Lentiviral (pCCL)
pSJ12 IFNLR1 (IRES-mCherry) Lentiviral (pTM945)
Empty vector
pTM945 IRES-mCherry Lentiviral (pCCL)
CRISPR, clustered regularly interspaced short palindromic repeats; IRES, internal ribosome entry site.
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NotI, 5¢-AAA AGC GGC CGC TCA TTC CTT ACT TCT
TAA ACT TT-3¢).
pMK03 is a lentiviral vector, derived from pTM897, that
carries the mouseMx1 gene promoter driving the expression of
the firefly luciferase gene. It is derived from pCCLsin.
cPPT.hPGK.GFP.pre (Follenzi and others 2000) in which a
cloning polysite was first inserted to replace the coding se-
quences, yielding pTM897. The firefly luciferase gene from
pGL4.16 (Promega) was inserted between the XhoI and XbaI
sites of the vector, and the Mx1 promoter was then cloned
from pBSK-Mx1, a gift from Peter Staeheli (Freiburg Uni-
versity, Freiburg, Germany), as a BamHI/BsaBI fragment.
The lentiviral vector pSJ12, used for expression of the
mouse IFN-l receptor, was obtained by cloning the Ifnlr1
ORF between the BamHI and XbaI sites of pTM945, a
lentiviral vector allowing the coexpression of the cloned
gene and of mCherry (Hermant and others 2013). The Ifnlr1
ORF sequence was subcloned in this plasmid from pcr2.1-
LICR2, kindly provided by Laure Dumoutier (de Duve In-
stitute, Brussels, Belgium).
Clustered regularly interspaced short palindromic
repeats Cas 9 editing
Gene inactivation was done with pX461 plasmid
(pSpCas9n-2A-GFP) coding for the Cas9 nickase and green
fluorescent protein (GFP) (Ran and others 2013a). The 2
single guide RNAs (sgRNAs) were designed using the MIT
clustered regularly interspaced short palindromic repeats
(CRISPR) design tool website (http://crispr.mit.edu). The
selected sgRNA pair (sgRNA1- Fw: 5¢-CAC CGT CAA
ATT CTG GCG GCT CAA G-3¢; Rev: 5¢-AAA CCT TGA
GCC GCC AGA ATT TGA C-3¢; sgRNA2- Fw: 5¢-CAC
CGA GAC CAC ATA AAC GTG ACG A-3¢; Rev: 5¢-AAA
CTC GTC ACG TTT ATG TGG TCT C-3¢) was targeting
exon 6 of the mouse Ifnar2 gene (GenBank: Y09865.1) and
exhibited no expected off-target cleavage site.
The sgRNAs were cloned into pX461 to form the plas-
mids pSJ37 and pSJ38. These constructs were cotransfected
in LKR10 cells, using TransIT-LT1 transfection reagent
(Mirus Bio LLC, Madison), according to the manufacturer’s
instructions. After 48 h, GFP-positive cells were sorted by
fluorescence activated cell sorting (FACS Aria III; BD
Biosciences) and cloned in 96-well plates. Clones were
screened for loss of type I IFN response with an antiviral
assay. Genome editing of the targeted exon was further
confirmed by sequencing (Genewiz).
ISG induction and quantification
ISG expression was measured by reverse transcription-
quantitative PCR. IFNAR2-knockout (KO) and wild-type
(WT) LKR10 cells were treated with 100 U/mL mouse IFN-
aA, 700 pg/mL mouse IFN-l3, or control supernatant (mock)
for 8 h before RNA extraction. Total RNA extraction, reverse
transcription, and SYBR Green quantitative PCR for mRNA
encoding mouse b-actin, Oasl2, and Usp18 were performed
as previously described (Paul and Michiels 2006).
Flow cytometry
For infection analysis, cells were dissociated with trypsin-
EDTA and suspended in phosphate-buffered saline (PBS)
containing 5% of filtered FCS and 0.5% of paraformalde-
hyde. Data acquisition was done with an LSRFortessa flow
cytometer (BD Biosciences) using FACSDiva software.
Data were analyzed using FlowJo 9.6.4. The rate of infec-
tion was defined as the percentage of mCherry-positive cells
24 h postinfection with 0.5 PFU/cell TM967.
For cell sorting, transduced cells were suspended in PBS
containing 1% FCS and 1 mM EDTA. mCherry- or GFP-
positive cells were cloned at 1 cell per well in 96-well plates
using the FACS Aria III (BD Biosciences).
Immunoblotting
STAT1, P-STAT1, and b-actin were detected by Western
blot using sodium dodecyl sulfate–polyacrylamide gel
electrophoresis gels containing 10% acrylamide and run in a
Tris-Glycine buffer. Blots were probed with anti-STAT1
polyclonal (sc-346; Santa Cruz Biotechnology, Heidelberg,
Germany), P-STAT1 monoclonal (#9167; Cell Signaling
Technology, Leiden, The Netherlands), and anti-b-actin
monoclonal (A5441; Sigma-Aldrich) antibodies.
IFNs
Mouse IFN-aA, IFN-b, IFN-l2, IFN-l3, and human IFN-
a2 were produced as described previously from 293T cells
transfected with pcDNA3-IFN-aA, pcDNA3-IFN-b (van
Pesch and others 2004), pcDNA3-IFN-l2 (pSJ1), and
pcDNA3-IFN-l3 (pSJ7). Human IFN-a2 was produced
similarly, using pcDNA3-IFN-a2 (pPH23). Supernatant
collected from 293T cells transfected in parallel with the
empty pcDNA3 vector was used for control treatment
(mock) of cells and diluted as for IFNs.
Recombinant mouse IFN-l3 (1789-ML-025) and human
IFN-l1 (1598-IL-025), IFN-l2 (1587-IL-025), and IFN-l3
(5259-IL-025) were purchased from R&D (R&D Systems,
Minneapolis). Recombinant human IFN-l4 was produced as
described (Hamming and others 2013). Mouse (ref 315-05)
and human (ref 300-02) IFN-g were purchased from Pe-
proTech (London, United Kingdom). GenBank accession
numbers for mouse and human IFN-l are listed in Table 2.
IFN quantification assays
IFNs were diluted in culture medium for cell treatment or
in reagent diluent for ELISA. Mouse IFN-l2 and IFN-l3
were quantified by ELISA. Mouse IFN-aA and human IFN-
a2 antiviral activities were quantified, as described pre-
viously, by a cytopathic effect reduction assay in mouse
BALB-3T3 and human Hela-M cells, respectively, using
Mengovirus (van Pesch and Michiels 2003). Similar assays
were conducted in human A549 cells and mouse LKR10
cells for quantification of IFN-l cross-species activity. IFN-
Table 2. GenBank Accession Numbers
for Interferon-l Sequences
Nucleotide Protein
mIFN-l2 NM_001024673.2 NP_001019844.2
mIFN-l3 NM_177396.1 NP_796370.1
huIFN-l1 NM_172140.1 Q8IU54.1
huIFN-l2 NM_172138.1 NP_742150.1
huIFN-l3 NM_001346937.1 AAN28264.1
huIFN-l4 NM_001276254.2 NP_001263183.2
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l4 was quantified by a cytopathic effect reduction assay in
A549 cells, using recombinant human IFN-l3 as a standard,
which was reported to have a similar specific activity
(Hamming and others 2013).
IFN-k2/3 ELISA
Mouse IFN-l2/3 measurement by ELISA was performed
using the mouse IFN-l2/3 DuoSet (R&D Systems), ac-
cording to the manufacturer’s protocol. Mouse sera were
diluted 5- to 10-fold, and bronchoalveolar lavage fluids
(BALFs) were diluted 5-fold.
Ultraviolet light irradiation
When required (in case of samples derived from infected
cells or mice), infectious virus present in biological samples
was ultraviolet light (UV)-inactivated. For UV inactivation,
2.5 mm thick fluid samples were exposed at fixed UV dose
(0.25–0.5–1–2 J/cm2) with the UV irradiation system Bio-
link 254 (Vilber Lourmat, Eberhardzell, Germany), either in
24- (470mL) or in 96-well (80mL) plate. UV-exposed
samples were titrated on BHK-21 cells by a standard plaque
assay to confirm virus inactivation.
To confirm that the UV irradiation procedure that was es-
tablished for picornaviruses effectively inactivates respiratory
syncytial virus (RSV), 3 samples of 470mL containing 1.5· 106
PFU of RSV were exposed to 2 J/cm2 with the UV irradiation
system Bio-link 254 at room temperature in a 24-well plate
(UV irradiated samples). As controls 3 similar samples of
470mL containing 1.5· 106 PFU of RSV were incubated at
room temperature in a 24-well plate (untreated samples). The
titers of replicating RSV in the UV irradiated and untreated
samples were determined by plaque assay using Vero cells.
IFN luciferase assay
Cells were seeded at 160,000 cells per well in 24-well
plates for cell supernatant and recombinant IFN analysis or
at 32,000 cells per well in 96-well plates for mouse serum
and BAL analysis. Forty-eight hours after seeding, cells
were treated with IFN-l2/3 or mock-treated or incubated
with UV-treated mouse serum (50- and 100-fold dilutions)
or BAL (5-fold dilutions). Samples were diluted in culture
medium. Recombinant mouse IFN-l3 provided in the
ELISA Kit was used as a standard.
Firefly luciferase activity was measured 6 h after treatment
using the luciferase assay system (Promega). Twenty micro-
liters and 100-mL lysis buffer were used in 96- and 24-well
plates, respectively; 10mL of the lysate was mixed with 25mL
of substrate for detection. Luminescence was measured with a
GloMax 20/20 luminometer (Promega). The limit of detection
(LOD) for each test was established based on the mean of
mock-treated samples, plus 3 standard deviations, in all assays.
Viruses
TM967 is a Theiler’s murine encephalomyelitis virus
(TMEV) (strain DA) derivative that carries a capsid adapted
to infect L929 cells and the ORF encoding the mCherry
fluorescent protein cloned as a XbaI/BsiWI fragment to re-
place codons 5–67 of the leader protein coding region, in the
pKJ6 vector ( Jnaoui and Michiels 1998). Mengovirus
(a strain of encephalomyocarditis virus) used for IFN bio-
assay is an attenuated variant that has been described pre-
viously (Hermant and others 2013). Those viruses were
quantified by plaque assay on BHK21 cells.
RSV propagation and enrichment were performed as de-
scribed in Schepens and others (Schepens and others 2014).
Mice and viral infection
Mouse experiments were conducted according to the na-
tional (Belgian Law 14/08/1986 and 22/12/2003, Belgian
Royal Decree 06/04/2010) and European (EU Directives 2010/
63/EU, 86/609/EEG) animal regulations. Animal protocols
were approved by the Ethics Committee of Ghent University
(permit no. LA1400091, approval ID 2013-030). All efforts
were made to avoid or ameliorate suffering of animals.
Specific pathogen-free female BALB/c mice at the age of 7–
8 weeks were purchased from Charles River. The mice were
housed in a specific-pathogen-free temperature controlled
environment with 12-h light/12-h dark cycles and given water
and food ad libitum. Mice were used at 9 weeks of age after
adaptation in the animal room for 1 week. For challenge, the
mice were sedated with isoflurane and infected intranasally
with 4· 106 PFU of human RSV. Mock infection of the control
group was performed with Hank’s balanced salt solution.
Five days postinfection, BAL was isolated under anesthesia
with an intraperitoneal injection of avertin (2.5% in PBS). A 23-
gauge cannula was inserted into the trachea, and cells were
collected by washing the airway lumen twice with 0.5 mL PBS
containing 0.05 mM EDTA. After removing the cells by cen-
trifugation (5 min at 400g), the BALF was stored at -80C.
Serum samples from norovirus-infected and plasmid-
electroinjected mice were reused from a previously published
experiment (Rocha-Pereira and others 2018) to minimize
animal experimentation.
Statistics
Statistical analysis was performed using Prism 7 soft-
ware (GraphPad Software, San Diego, CA). [***P < 0.001,
**P < 0.01, *P < 0.05, and ns no statistically significant
difference (P ‡ 0.05)].
Results
Species-specific activity of mouse and human IFN-k
Unlike mouse and human type I IFNs (IFN-a/b) that exhibit
strong species specificity, type III IFNs were reported to act in
a cross-species manner. To confirm whether a mouse cell-
based bioassay would permit the detection of IFN-l subtypes
from 2 different mammalian species, the species specificity of
mouse and human type III IFNs was reexamined. Cross-
reactive antiviral activity was systematically compared in a
cytopathic effect reduction assay, using epithelial cell lines
from mouse (LKR10) and human (A549) origin.
As expected, type I human (IFN-a2) and mouse (IFN-
aA) IFNs were extremely species-specific in the antiviral
assay, with an activity difference higher than 10,000-fold
when applied to mouse and human cells. IFN-l exhibited
some level of species specificity although much less than
type I IFNs (Fig. 1A). Mouse IFN-l3 displayed the most
pronounced species specificity. For a quantity that yielded
the same antiviral activity in mouse cells, IFN-l3 was 25
times less active in human cells than the closely related
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mouse IFN-l2. Human IFN-l1, IFNl-2 and, to a lesser
extent, IFNl-3 exhibited significant antiviral effect on
mouse epithelial cells.
As IFN-l4 has been shown to have a specific activity
similar to that of human IFN-l3 in human cells, it was
quantified accordingly using the antiviral assay (Hamming
and others 2013). Remarkably, human IFN-l4 displayed
much more antiviral activity on mouse cells than equivalent
amounts of human IFN-l3. Accordingly, treatment of
LKR10 cells with concentrations of human IFN-l3 and IFN-
l4 that yielded equivalent antiviral activities in human cells
resulted in clear STAT1 phosphorylation after IFN-l4 but
not after IFN-l3 treatment (Fig. 1B).
Generation of IFNAR2 knockout LKR10 cells
In line with their epithelial origin, mouse LKR10 cells
respond to IFN-l. To ensure a selective detection of type III
IFNs, the gene coding for the IFNAR2 subunit of the type I
IFN receptor was inactivated using the double nickase
CRISPR/CRISPR-associated (Cas) 9 technology (Ran and
others 2013b). An LKR10-IFNAR2-KO clone was selected
for the absence of response to type I IFN and intact response
to type III IFN. Sequencing of the targeted exon revealed
frameshift mutations in both Ifnar2 alleles, resulting in
premature STOP codon appearance. In contrast to IFN-l
treatment, IFN-a treatment of this clone failed to induce the
expression of the IFN-stimulated genes, Oasl2 (Fig. 2A) and
Usp18 (Fig. 2B), and to protect against infection with
TM967, a TMEV derivative expressing mCherry (Fig. 2C).
Generation and characterization of Mx1-luciferase
reporter cells for type III IFN detection
To develop IFN-l reporter cells, the LKR10-IFNAR2-KO
clone was transduced with a lentiviral vector encoding the
firefly luciferase gene under the control of the Mx1 pro-
moter. Among the clones tested for luciferase activity in-
duction after IFN-l treatment, the best one displayed not
more than 10-fold luciferase activity induction. To try to
boost the reporter gene responsiveness to IFN-l, this clone
was transduced with SJ12, a lentiviral vector that coex-
presses the mouse IFNLR1 and mCherry. Transduced cells
were sorted, based on mCherry expression, and cloned.
A selected clone, named ‘‘Fawa-l-luc,’’ responded vigor-
ously to IFN-l3. This clone displayed increased constitutive
STAT1 expression and strong STAT1 phosphorylation after
IFN-l3 but not after IFN-a treatment (Fig. 2D). A signifi-
cant luciferase activity increase was measured in Fawa-l-
luc cells as soon as 1 h after treatment with 700 pg/mL
(quantified by ELISA) of mouse IFN-l3. Maximal induc-
tion was reached within 6 h and lasted up to 16 h post-
treatment (Fig. 3A).
Fawa-k-luc cells allow sensitive detection
of mouse IFN-k2 and -3
The sensitivity of the Fawa-l-luc assay was compared to
that of an available ELISA test for mouse IFN-l. Mouse
IFN-l2 and -3 produced by transfected 293T cells and re-
combinant mouse IFN-l3 were quantified in parallel by
ELISA and the Fawa-l-luc assay. In the ELISA, responses
were linear between 1,000 and 16.25 pg/mL, the experi-
mental LOD of this test (Fig. 3B). In the Fawa-l-luc assay,
linearity was reached in a narrower concentration range
(1.95–62.5 pg/mL for mouse IFN-l2; 3.9–125 pg/mL for
mouse IFN-l3), but a higher sensitivity was observed with
the detection limit being below 1.95 pg/mL and 3.9 pg/mL,
for IFN-l2 and -3, respectively (Fig. 3C, D). Based on
ELISA quantification, mouse IFN-l2 bioactivity in this as-
say was 2-fold higher than that of mouse IFN-l3.
Importantly, after up to 29 passages, the intensity of the
luciferase signal in the Fawa-l-luc cells tended to decrease,
but the sensitivity of the bioassay was preserved because
FIG. 1. Species specificity of mouse and human type III IFNs. (A) Table showing the relative antiviral activity of mouse
and human IFN-l on mouse LKR10 and human A549 cells. Species specificity index was calculated as the ratio between the
relative antiviral activity on cells of homologous to nonhomologous species (eg, for mouse IFN: relative activity in mouse
cells/relative activity in human cells). Relative activities in a given cell line were calculated as the IFN dilutions (starting
from 1 ng/mL) that yielded similar antiviral activities. *Due to the low amount of IFN-l4 available, the initial concentration
of this IFN was estimated by comparison with human IFN-l3 antiviral activity that was reported to have a similar specific
activity. (B) Western blot showing STAT1 phosphorylation in mouse LKR10 cells 30 min after treatment with control
medium (mock) or IFN-l. Concentrations of human (Hu) IFN-l3 (615 pg/mL) and IFN-l4 that yielded the same antiviral
activity on human A549 cells were used. As a control, mouse IFN-l3 was used at a concentration (2.5 ng/mL) showing
equivalent antiviral activity as human IFN-l4 on mouse cells. Results are representative of 3 experiments.
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the background activity also decreased with high passage
numbers.
To confirm the specificity of Fawa-l-luc cells for IFN-l,
we also evaluated any possible luciferase induction after
treatment with type I and type II (ie, IFN-g) IFNs. As ex-
pected, no signal was observed after treatment with up to
2,500 IU/mL of either mouse IFN-aA or IFN-b. Human
IFN-g also failed to induce a detectable luminescent signal
in the Fawa-l-luc cells in the tested concentration range (0–
25 ng/mL). The LOD for mouse IFN-g was 12.55 ng/mL, a
concentration at least 10-fold higher than what is observed
in mouse fluids in infectious contexts (Pomeroy and others
1998; Claser and others 2017). IFN-g is thus not expected to
interfere with IFN-l detection in biological samples.
Detection of human IFN-k subtypes
We tested the sensitivity of our bioassay for human IFN-l
detection. Responses were analyzed individually for all 4
human IFN-l subtypes (Fig. 4A–D). As their cross-species
activity differed, different detection sensitivities were reached
with our mouse cell-based reporter assay: 15.125 pg/mL for
IFN-l1, 500 pg/mL for IFN-l2, 31.25 pg/mL for IFN-l3, and
1.95 pg/mL for IFN-l4. The bioassay turned out to be ex-
tremely sensitive for human IFN-l4 detection. It is, however,
worth noting that the recombinant IFN-l4 stock concentra-
tion was determined by comparison of its activity with that of
a human IFN-l3 standard.
Ultraviolet light resistance of IFN-k
When testing biological samples, potential occurrence of
infectious virus may interfere with the viability of reporter cells.
It is therefore important to inactivate infectious viruses in such
samples. As IFN-l had previously been shown to be acid labile
(Kugel and others 2011), UV inactivation of the virus was
preferred. We thus tested whether virucidal UV doses would
affect IFN-l activity. To this end, TM967 virus, mouse IFN-l2,
and mouse IFN-l3 were irradiated with increasing UV doses.
Mock- and UV-exposed samples were then analyzed with the
bioassay for mouse IFN-l2 and IFN-l3 detection and by plaque
assay to determine viral titers.
FIG. 2. IFN-stimulated gene expression, STAT1 phosphorylation, and antiviral activity in response to IFN-aA and IFN-
l3 treatment in LKR10 derived cells. (A, B) Amounts of Oasl2 (A) and Usp18 (B) transcripts per 106 b-actin copies
detected in WT and IFNAR2-KO LKR10 cells 24 h after treatment with mouse IFN-aA, IFN-l3 (mIFN-l3), or control
medium (mock). (C) Percentage of mCherry-positive cells in WT and IFNAR2-KO LKR10 cells measured by flow
cytometry 24 h postinfection with 0.5 PFU/cell TM967. Cells were pretreated with mouse IFN-aA, mIFN-l3, or mock for
7 h before infection. (D) Western blot showing STAT1 phosphorylation and expression in LKR10 cells and derivatives.
Cells were treated for 30 min before protein extraction. Reproducible results were obtained in 3 independent experiments.
(A–D) 100 U/mL IFN-aA and 700 pg/mL mIFN-l3 were used for treatment. Student’s t-test: ***indicates a significant
difference of the IFN-treated groups compared to the mock-treated group (A–C). ns, nonsignificant. WT, wild-type.
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A 2 J/cm2 UV exposure was sufficient to ensure a virus
titer reduction of more than 100,000-fold (5.5 · 105 PFU to
<1 PFU). At this UV dose, mouse IFN-l2 activity was not
significantly reduced and mouse IFN-l3 showed a bioac-
tivity reduction of less than 25% (Fig. 5A).
Similarly, IFN-l1 and IFN-l4 bioactivities were reduced
by 25%, while human IFN-l2 and IFNl-3 were slightly
more sensitive to irradiation, with about 2-fold activity de-
crease (Fig. 5B).
Highly sensitive detection of IFN-k2/3 in mouse
serum and bronchoalveolar lavage fluids
We then compared the sensitivities of the Fawa-l-luc and
of the ELISA assays to detect IFN-l in mouse serum and
BAL samples. IFN-l was first quantified in the serum of
mice that were either injected intramuscularly with an IFN-
l3 expressing plasmid (pCS59), thus expected to produce
circulating IFN-l, or infected with mouse norovirus (Rocha-
Pereira and others 2018).
A preliminary test revealed that the minimal serum dilution
that did not interfere with spiked-in IFN-l detection was 16-
fold for the bioassay and 5-fold for the ELISA (Fig. 5C, D)
with both the Fawa-l-luc and ELISA assays. IFN-l was
clearly detected at day 2 and 4 in the serum of mice that were
electroinjected with the IFN-l3 expressing plasmid, as well as
at day 3 postnorovirus infection (Fig. 6A, B). At day 2 after a
single IFN-l3 injection, the cytokine was detectable in 1 out of
4 mice by ELISA and in 3 out of 4 mice by the bioassay. The
detection limit was higher for the ELISA (194 pg/mL) than for
the bioassay (9.29 pg/mL), showing the higher sensitivity of
the luciferase-based bioassay (Fig. 6A, B).
Next, we compared IFN-l detection by the Fawa-l-luc as-
say and by ELISA in BALF of BALB/c mice that were mock
infected or infected with RSV. BALF and lungs were collected
5 days postinfection. Plaque assay revealed that BALF of all
infected mice contained between 1.8· 102 and 7.33· 102 PFU/
mL of live replicating virus. The used UV irradiation proce-
dure proved to readily inactivate RSV (RSV titer reduction of
more than 46,000-fold; 4.6· 104 PFU to <1 PFU). Five-fold
diluted control BALF did not modify IFN-l2/3 detection in
any of the 2 assays. Using 5-fold dilutions of the BALF as in
the bioassay, we failed to detect any IFN-l by ELISA
(Fig. 6C). In contrast (Fig. 6D), IFN-l was detected by Fawa-
l-luc assay at a very low concentration in the BALF of the
RSV infected mice (5/6) and not detected in the control group.
FIG. 3. Mouse IFN-l titration using Fawa-l-luc reporter cells and ELISA. (A) Luciferase activity detected in Fawa-l-luc
cells treated for the indicated time with 700 pg/mL mouse IFN-l3 (mIFN-l3). (B) Quantification by ELISA of mouse IFN-
l2 (mIFN-l2) and mIFN-l3 in cell supernatants. Two fold serial dilutions (800–12,800-fold) were quantified in quintu-
plicate. (C, D) Dose–response of mIFN-l2 and mIFN-l3 supernatants was measured in triplicate Fawa-l-luc cells and is
representative of at least 3 independent experiments. Cells were treated for 6 h with 2-fold serial dilutions. Data points in the
linear range of the assays were plotted, and linear regression analysis was performed. LOD is based on the mean of mock
treated cell signal, plus 3 standard deviations. ELISA, enzyme-linked immunosorbent assay; LOD, limit of detection; RLU,
relative light units; R2, coefficient of regression.
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FIG. 4. Human IFN-l response in the mouse Fawa-l-luc reporter cells. (A–D) Dose–response of human (hu) recombinant
(A) IFN-l1, (B) IFN-l2, (C) IFN-l3, and (D) IFN-l4 as measured in triplicate. (A–D) Data points in the linear range of the
assays were plotted, and linear regression analysis was performed. LOD is based on the mean of mock treated cell signal,
plus 3 standard deviations.
FIG. 5. Sensitivity of IFN-l to UV exposure and influence of serum on reporter cell activity and ELISA detection. (A, B)
UV sensitivity of mouse and human IFN-l. (A) Relative luciferase activities of Fawa-l-luc cells treated with 250 pg/mL of
mouse IFN-l2 (mIFN-l2) or IFN-l3 (mIFN-l3) supernatants irradiated (n= 3) under 0.25, 0.5, 1 and 2 J/cm2. (B) Percentage
of IFN-l activity (mean and SD) remaining after UV treatment (n= 3) at 2 J/cm2. IFN activity was measured in Fawa-l-luc cells
for IFN concentrations that yielded equivalent luciferase activities (20,000 RLU) before UV treatment (250 pg/mL mIFN-l2 and
mIFN-l3, 125 pg/mL human IFN-l1, 10 ng/mL huIFN-l2, 500 pg/mL huIFN-l3, and 62.5 pg/mL huIFN-l4). (C, D) Influence
of serum dilution on IFN-l detection by Fawa-l-luc cells (C) and ELISA (D). (C) Fawa-l-luc cells were treated in triplicate with
fixed doses of 15 and 250 pg/mL mIFN-l2 supernatant and with 2-fold serial dilutions (2–128-fold) of control mouse serum. (D)
125 pg/mL recombinant mIFN-l3 was mixed with 2-fold serial dilutions of control mouse serum (2.5–10-fold) before detection
by ELISA. (A–C) Reporter cells were exposed to IFN for 6 h before luciferase assay. Student’s t-test: */**/***denotes a
significant difference in signal compared to no UV exposure (A) or the absence of serum (C). UV, ultraviolet light.
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We conclude that the Fawa-l-luc-based assay described
in this study allows to quantify IFN-l from biological
samples in a highly sensitive way.
Discussion
We reexamined the species specificity of IFN-l and high-
lighted a previously overlooked difference in bioactivity be-
tween mouse and human type III IFNs. Mouse IFN-l3
displayed a surprising species specificity, with a 50-fold dif-
ference in relative antiviral activity when applied to LKR10
(mouse) and A549 (human) cells. This contrasted strongly
with the closely related mouse IFN-l2 (93% amino acid se-
quence identity), which displayed little species specificity and
was 25 times more active in human cells than mouse IFN-l3.
In contrast, human IFN-l4 displayed a strikingly strong
activity on mouse cells compared to human IFN-l3. Al-
though IFN-l4 is not expressed in mouse and rat, it is highly
conserved in many mammalian species (Key and others
2014) where it was shown to be cross-reactive. The non-
human IFN-l4 orthologs were reported to activate IFNLR1
in human cells, sometimes with a higher efficacy than hu-
man IFN-l4 (eg, dog IFN-l4) (Paquin and others 2016).
The mouse cell response to human IFN-l4 is thus in line
with the ability of IFN-l4 to be cross-reactive among
mammalian species, although we do not have any physio-
logical explanation for this phenomenon.
IFN-l proteins follow the typical class II cytokine
structure, consisting of 6 secondary structure elements (A–
F) (Pestka and others 2004). Helix A is involved in both
IFNLR1 and IL10Rb binding, while helix D binds IL10Rb
and helix F binds IFNLR1 (Gad and others 2010). Among
amino acid residues that have been characterized as crucial
for IFNLR1 binding and activation (Gad and others 2010), a
few divergences are observed between sequences from
mouse and human IFN-l (Fig. 7).
Notably, the more species-specific mouse IFN-l3 has 4
amino acid residues in a helices A and F that diverge from
the 5 other IFN-l sequences, including the related mouse
IFN-l2. In helix A, Gly37 uniquely replaces the Asp residue
present in the other sequences. In helix F, 3 residues are
unique to mouse IFN-l3: Asp 150 (Ala/Asp), Gln158
FIG. 6. Detection of type III IFN in biological samples by ELISA and bioassay. (A, B) IFN-l2/3 detection by ELISA (A)
and bioassay (B) in the serum of AG129 mice 2 or 4 days after electroinjection of mouse IFN-l3 (mIFN-l3) expressing
(pCS59) or empty (pcDNA3) plasmids, 2 days after injection of pCS59, or 3 days after infection with mouse norovirus. IFN-
l detection in the serum by ELISA was performed without UV exposure to keep maximal sensitivity. (C, D) IFN-l2/3
detection by ELISA (C) and bioassay (D) in the bronchoalveolar lavage of BALB/C mice, 5 days postinfection with RSV,
compared to control mice (mock). BALF were UV-exposed before testing. (A–D) The horizontal dotted line represents the
LOD. Mann–Whitney: */**indicates a significant difference compared to pcDNA3 group at days 2 or 4 (A, B) or compared
to mock (D). BALF, bronchoalveolar lavage fluid; RSV, respiratory syncytial virus.
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(Arg/Gln), and Leu161 (Thr/Leu). Future site-directed
mutagenesis studies could help defining the key residues
involved in the species specificity.
We designed a highly sensitive bioassay named ‘‘Fawa-l-
luc’’ based on luciferase reporter cells, specific for IFN-l
detection and quantification. The bioassay is based on a cell
line that is naturally responsive to IFN-l in which the type I
IFN receptor gene was inactivated. Overexpression of the
mouse IFNLR1 receptor in those cells led to increased in-
duction of the reporter gene after IFN-l treatment.
Unlike previously described bioassays, such as HL-116
fibroblasts stably transfected with the human IFNLR1 (Uze
and Monneron 2007), Fawa-l-luc cells permit the selective
detection of type III IFN because they lack the type I IFN
receptor. They also fail to respond to IFN-g concentrations
that are reached in infected mouse serum. This novel bioassay
is efficient in measuring IFN-l from mouse BAL and serum.
IFN-l activity was hardly affected by UV exposure at
virucidal doses, thus allowing detection in infected biolog-
ical fluids. The high sensitivity of the assay permits sparing
biological material as 10-fold more diluted serum samples
could be used for bioassay detection (50–100-fold dilution)
compared to the ELISA (5–10-fold). When cell toxicity of
the tested samples is suspected, cell viability may inde-
pendently be confirmed with nonlytic viability assays such
as Resazurin-based tests, which are compatible with lucif-
erase detection. Importantly, our bioassay offers a physio-
logic analysis, attesting of the functionality of the IFN-l
present in the samples, irrespective of specific activity.
The bioassay also allows to detect human IFN-l. Given
the divergent cross-species activity and the higher UV la-
bility of the human type III IFNs, the bioassay might be used
for individual subtype analysis, but would not fit for their
detection in complex biological samples. Finally, it offers a
sensitive detection of the divergent IFN-l4, for which no
efficient commercial test is available.
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